USA-based Eli Lilly (NYSE: LLY) has announced revenues of $7.3
billion in the final quarter of 2022, a 9% decrease from the same
period of last year, around what most analysts had anticipated.
Net income was reported at $1.9 billion, an increase of 12%, with
earnings per share (EPS) of $2.14.
Excluding COVID-19 antibodies, total worldwide volume in the
fourth quarter increased 13%.
Total revenues for 2022 grew 1% to reach $28.5 billion.
The decline in…
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.
Read More: Lower prices and exchange rate effects hold Eli Lilly back